Treatment of skin disorders with compositions comprising an EGFR inhibitor

US11633399B2 · kind B2 · utility

Assignee

• Sol-Gel Technologies Ltd. · IL

Inventors

• Moshe ARKIN · Kfar Shmaryahu, IL
• Marcel ZIGHELBOIM · Kiryat Motzkin, IL
• Ori Nov · Tarom, IL
• Ofer Toledano · Kfar Sava, IL
• Karine NEIMANN · Nes Ziona, IL

Key dates

• Filing date: Jan 8, 2020
• Grant date: Apr 25, 2023
• Expiry date: Jan 8, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K47/32
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to compositions and methods of treatment of skin or mucosal disorders by administration of compositions comprising at least one EGFR inhibitor, such as topical compositions comprising erlotinib. The compositions of this invention are useful for the treatment, prevention or amelioration of skin or mucosal disorders like psoriasis, palmoplantar psoriasis, acquired palmoplantar keratosis, eczema, ichtyosis vulgaris, non-melanoma skin cancer, actinic keratosis, a keratinization skin disorder, a keratinization mucosal disorder, pachyonychia congenita, hidradenitis suppurativa, Gorlin syndrome, prurigo nodularis and prurigo pigmentosa.